Abstract
Rabies infection in humans is still a major public health problem, causing upwards of 20,000 deaths per year. The prevalent vaccine is still the nerve-tissue vaccine, which, although improved, necessitates the use of long and painful application schedules and fails to provide safe and reaction-free protection. A new generation of low-cost, purified rabies vaccines released in the last 2 years promises a revolution in rabies immunization in less-developed, rabies endemic countries, providing protection comparable to that of human diploid cell vaccine at the cost of Semple-type vaccine. Devising an appropriate technology for human rabies immunization includes new regimens of administration, one of which, a revised intramuscular regimen requiring only four doses and three clinic visits, proved highly efficient for postexposure treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
